Effect of thymosin-α(1) on T-helper 1 cell and T-helper 2 cell cytokine synthesis in patients with hepatitis B virus e antigen-positive chronic hepatitis B.
Jiang. Y-F YF; Ma. Z-H ZH; Zhao. P-W PW; Pan. Y Y; Liu. Y-Y YY; Feng. J-Y JY; Niu. J-Q JQ
Key Findings
- TA‑1 treatment increased the proportion of blood immune cells producing Th1 cytokines (IL‑2, IFN‑γ, TNF‑α) and the Th2 cytokine IL‑4.
- Cytokine production rose gradually over the 52‑week period and eventually exceeded levels seen in healthy controls for IFN‑γ and IL‑4.
- A higher dose of TA‑1 (3.2 mg) showed stronger antiviral effects than the lower dose (1.6 mg).
Practical Outcomes
- For biohackers interested in immune modulation, TA‑1 appears to be a potent way to raise IFN‑γ and other cytokines, which could help fight viral infections. The study suggests a dose‑response, so a 3 mg‑range daily dose might be more effective than 1.5 mg, but the data are limited to hepatitis B patients, so benefits in healthy people remain speculative. Use caution and consider medical supervision before experimenting.
Summary
In a small trial of people with chronic hepatitis B, giving the peptide thymosin‑alpha‑1 (TA‑1) for a year boosted the activity of immune cells that make important signaling proteins (cytokines) like IFN‑γ, IL‑2 and IL‑4. The boost grew over time, and a higher dose (3.2 mg) worked better than the lower dose (1.6 mg). This shows TA‑1 can ramp up both Th1 and Th2 immune pathways, especially IFN‑γ, in a disease setting.
Abstract
Thymosin-α(1) (TA(1)) has been shown to be effective treatment for chronic hepatitis B virus (HBV) infection. This study investigated the immune response after TA(1) monotherapy in 25 HBV e antigen (HBeAg)-positive patients randomized to receive either 1.6 mg active TA(1) (group A), 1.6 mg recombinant TA(1) (group B) or 3.2 mg recombinant TA(1) (group C) monotherapy for 52 weeks. The percentages of T-helper 1 (T(h)1) cytokine-producing T-cells (interleukin-2 [IL-2], interferon-γ [IFN-γ], tumour necrosis factor-α) and T(h)2 cytokine-producing T-cells (IL-4) were analysed using flow cytometry. In all patients treated with TA(1), cytokine levels and the proportion of peripheral blood mononuclear cells producing these cytokines were significantly increased, compared with baseline and healthy controls. The proportions of each cytokine-producing cell increased gradually over time and were restored to normal levels, and proportions of IFN-γ and IL-4-producing cells reached higher levels than in normal (healthy) controls. The results showed that treatment with TA(1) increased cytokine production, especially IFN-γ, and higher-dose TA(1) exhibited better efficacy against HBV, compared with other treatments studied.
Study Information
pubmed
2010
2010-12-01T00:00:00.000Z
10.1177/147323001003800620
14
24